ECB’s Nagel: No clear signs that inflation has fed through to price and wage setting
European Central Bank (ECB) policymaker and Bundesbank President Joachim Nagel said in a speech in Sorrento, Italy during the European trading session on Monday that the impact of energy shock-driven inflation has yet not fed into wage growth.
Comments
Longer-term market-based and expert expectations remain consistent with the Eurosystem’s 2% inflation target.
Upward risks dominate the inflation outlook; uncertainty calls for flexibility, not inaction.
Gas prices are especially vulnerable because storage levels are low.
Europe may need to buy substantially higher volumes during the winter.
The destruction of refining capacity is driving up prices for refined petroleum products significantly.
Drought, wildfires and fertiliser shortages also pose risks to food prices.
This was increasing the relative attractiveness of bonds among reserve asset managers.
The case for diversification into gold remains significant given continued geopolitical stress and the credit risk associated with high debt levels.
Market reaction
No immediate impact on the Euro (EUR) from ECB Nagel's comments. At press time, EUR/USD is down 0.3% to near 1.1215 even after recovering a majority of its early losses.
Nagel flags inflation risks, keeps Euro bulls
ECB’s Nagel delivers a stronger-than-usual signal, with a 7.2/10 FXS Speechtracker score versus a 6.6/10 historic average, pointing to a modest hawkish shift. The emphasis that “upward risks dominate the inflation outlook” suggests reluctance to ease policy quickly, which tends to underpin the Euro as markets reassess the path of future rate cuts.
Nagel’s call that “uncertainty calls for flexibility, not inaction” reinforces a bias toward keeping options open for further tightening if needed, rather than committing to a dovish stance. At the same time, noting “no clear signs that inflation has fed through to price and wage setting” tempers the hawkish tone, but overall the balance of risks still leans toward supporting the Euro on expectations of a more persistent anti-inflation stance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Lumexa shares rise after Truist gives "Buy" rating
On October 5th, shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading to $10.6. Brokerage Truist Securities initiated coverage with a “Buy” rating and a target price of $18, which implies about 74% upside from the previous trading day’s close. The company offers diagnostic imaging services, including MRI, CT, and PET scans, as well as X-ray, ultrasound, and mammography services. All five brokerages currently covering LMRI have assigned it a “Buy” or higher rating, with a median target price of $17.50, according to data compiled by LSEG. As of the previous close, LMRI’s share price has declined 44.22% year-to-date. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to the possibility of errors or missing context in automated translations, Reuters does not guarantee their accuracy and provides these translations solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Roche secures rights to Alector's Parkinson's therapy for up to $1.27 billions, Alector shares surge
Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.
Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris
08:10 AM EDT, 10/05/2026 (MT Newswires) -- Harrow (HROW) said Monday that it has closed its earlier stated acquisition of Tyrvaya from Viatris (VTRS), acquiring worldwide rights to the nasal spray, except for Japan. Harrow said that, in accordance with the terms reported in August, the company paid $30 million in cash at closing and may pay up to $70 million in sales-based milestones. Tyrvaya is an FDA-approved nasal spray for dry eye disease, Harrow said. Harrow said it expects the product to generate more than $30 million in revenue next year.
Ecarx Completes Acquisition of Flyme Software Business
08:10 AM EDT, 10/05/2026 (MT Newswires) -- Ecarx (ECX) said Monday that it has closed its acquisition of the entire Flyme software business portfolio, including the Flyme Auto in-vehicle cockpit operating system and a cross-device Flyme operating system. The company said it paid 1.8 billion Chinese renminbi ($266 million) in cash, about 70% of which was funded by syndicated bank loans from Chinese commercial banks and roughly 30% from internal sources. After closing, Ecarx said it will provide the acquired business with 200 million renminbi to support its operations. Shares of Ecarx were up 5.8% pre-bell Monday.
Crypto prices
More
